FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
Executive Summary
FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.
You may also be interested in...
‘Weight Management’ Guidance Changes From FDA Could Tip Scales In Obesity Reimbursement Debate
Expected revision to the 2007 draft might more clearly communicate that obesity is a disease than the earlier guidance, and could provide advice on getting indications for treating complications. If US FDA embraces the new thinking, it could help build the case for Medicare reimbursement.
Weighty Issues: GW Obesity Outcomes Project Tests Model For Patient Input In Drug Development
A stakeholder project on obesity treatment outcomes will complete its work this summer, setting the stage for FDA to rethink efficacy endpoints for weight loss drug development. The closed-door project is happening in parallel with public advisory committee discussions on pending applications and safety standards. One impact will be to shape more formal patient-centered drug development activities in years to come.
FDA Says Qnexa Needs CV Outcome Trial, Asks Cmte. To Consider Pre- Or Post-Approval Timeframe
Endocrinologic and Metabolic Drugs Advisory Committee also will weigh in on a teratogenicity risk management strategy for Vivus’ weight-loss drug during a Feb. 22 meeting.